ANI Pharmaceuticals (NASDAQ:ANIP) Issues FY 2024 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) updated its FY 2024 earnings guidance on Friday. The company provided earnings per share guidance of 4.900-5.050 for the period, compared to the consensus earnings per share estimate of 4.720. The company issued revenue guidance of $594.0 million-$602.0 million, compared to the consensus revenue estimate of $590.3 million. ANI Pharmaceuticals also updated its FY24 guidance to $4.90-5.05 EPS.

ANI Pharmaceuticals Trading Up 5.2 %

Shares of ANIP stock opened at $61.44 on Friday. ANI Pharmaceuticals has a 12 month low of $48.20 and a 12 month high of $70.81. The company has a market cap of $1.29 billion, a PE ratio of 52.51 and a beta of 0.71. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. The business’s 50 day moving average is $58.66 and its two-hundred day moving average is $61.52.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ANIP. Piper Sandler assumed coverage on shares of ANI Pharmaceuticals in a report on Friday, October 11th. They issued an “overweight” rating and a $68.00 target price on the stock. Raymond James boosted their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Truist Financial raised their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 22nd. HC Wainwright reiterated a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Tuesday, September 17th. Finally, StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $77.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.